Form 4 Tracker
Amneal Pharmaceuticals, Inc.
AMRX

35 insider filings · Latest: Sep 17, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Aug 13, 2025Aug 13 2:41 PMKonidaris Tasos
Proposed Sale
111,635$9.02$1.0M—

View →

Aug 12, 2025Aug 12 8:06 PMBOYER ANDREW S
Proposed Sale
33,436$9.09$304.1K—

View →

Aug 12, 2025Aug 12 8:04 PMDaly Jason B.
Proposed Sale
22,000$9.00$198.0K—

View →

Aug 12, 2025Aug 12 7:09 PMShah Nikita
Proposed Sale
50,000$9.06$453.0K—

View →

May 16, 2025May 16 8:02 PMShah Nikita
Proposed Sale
49,140$7.50$368.6K—

View →

May 12, 2025May 12 8:07 PMKiely John
Proposed Sale
50,000$7.57$378.5K—

View →

May 2, 2025May 2 8:38 PMGautam Patel
Proposed Sale
160,000$7.74$1.2M—

View →

Mar 14, 2025Mar 14 11:32 PMPatel Tushar Bhikhubhai
Proposed Sale
5,000,000$8.75$43.8M—

View →

Mar 5, 2025Mar 5 10:02 PMAlva Emily Peterson
Proposed Sale
85,000$8.87$754.0K—

View →

Mar 5, 2025Mar 5 10:00 PMBOYER ANDREW S
Proposed Sale
125,000$8.87$1.1M—

View →

Mar 5, 2025Mar 5 9:57 PMDaly Jason B.
Proposed Sale
90,000$8.80$792.0K—

View →

Mar 5, 2025Mar 5 3:00 PMKonidaris Tasos
Proposed Sale
100,000$8.84$884.0K—

View →

Nov 22, 2024Nov 22 3:39 PMKiely John
Proposed Sale
17,058$8.33$142.2K—

View →

Nov 21, 2024Nov 21 7:01 PMAutor Deborah M.
Proposed Sale
50,000$8.38$419.0K—

View →

Nov 15, 2024Nov 15 6:49 PMDaly Jason B.
Proposed Sale
57,322$8.50$487.2K—

View →

Jan 2, 2025—Gautam J Patel
Proposed Sale
320,000$8.00$2.6M—

View →

← Previous

Page 2 of 2

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Mar 3, 2026Mar 5 9:52 PMPatel ChintuDirector, Co-CEO
Option Exercise
793,875—0(D)

View →

Mar 4, 2026Mar 5 9:51 PMPatel Chirag K.Director, President & Co-CEO
Option Exercise
92,593—185,185(D)

View →

Mar 3, 2026Mar 5 9:51 PMPatel Chirag K.Director, President & Co-CEO
Option Exercise
793,875—0(D)

View →

Mar 4, 2026Mar 5 9:32 PMJason B. DalyEVP, Chief Legal Officer
Option Exercise
35,880—71,760(D)

View →

Mar 3, 2026Mar 5 9:32 PMJason B. DalyEVP, Chief Legal Officer
Option Exercise
390,939—0(D)

View →

Mar 4, 2026Mar 5 9:31 PMTasos KonidarisExecutive Vice President & CFO
Option Exercise
49,982—87,963(D)

View →

Mar 3, 2026Mar 5 9:31 PMTasos KonidarisExecutive Vice President & CFO
Option Exercise
589,883—0(D)

View →

Mar 4, 2026Mar 5 9:31 PMAndrew S BoyerExecutive Vice President
Option Exercise
38,195—76,389(D)

View →

Mar 3, 2026Mar 5 9:31 PMAndrew S BoyerExecutive Vice President
Option Exercise
510,758—0(D)

View →

Mar 4, 2026Mar 5 9:30 PMNikita ShahExecutive Vice President
Option Exercise
35,880—71,760(D)

View →

Mar 3, 2026Mar 5 9:30 PMNikita ShahExecutive Vice President
Option Exercise
472,619—0(D)

View →

Mar 2, 2026Mar 3 9:29 PMPatel ChintuDirector, Co-CEO
Grant/Award
544,663—354,031(D)

View →

Mar 2, 2026Mar 3 9:29 PMPatel Chirag K.Director, President & Co-CEO
Grant/Award
544,663—354,031(D)

View →

Mar 2, 2026Mar 3 9:28 PMNikita ShahExecutive Vice President
Grant/Award
130,718—65,359(D)

View →

Mar 2, 2026Mar 3 9:28 PMTasos KonidarisExecutive Vice President & CFO
Grant/Award
145,244—72,622(D)

View →

Mar 2, 2026Mar 3 9:27 PMJason B. DalyEVP, Chief Legal Officer
Grant/Award
130,718—65,359(D)

View →

Mar 2, 2026Mar 3 9:26 PMAndrew S BoyerExecutive Vice President
Grant/Award
130,718—65,359(D)

View →

← Previous

Page 2 of 2